Get to know Jayne Gershkowitz, Chief Patient Advocate at Amicus Therapeutics

TRNDS 2019 speaker, Jayne Gershkowitz is a passionate advocate and expert in a wide variety of issues affecting individuals with rare diseases and their families.

Jsyne Gershkowitz, Amicus Therapeutics, TRNDS 2019

May 18, 2019 | Taren Grom | WOW Podcast, PharmaVOICE

Jayne C. Gershkowitz joined Amicus in June 2006 and currently serves as Chief Patient Advocate. She founded Amicus’ Patient Advisory Boards program and manages Healing Beyond Disease™. She is a long-time patient advocacy professional with expertise in the LSD and broader rare disease community. Previously, Ms. Gershkowitz served as Executive Director at the National Tay-Sachs & Allied Diseases (NTSAD) Association. Her earlier career experience encompasses newspaper journalism; corporate and non-profit marketing communications; and social services.

Ms. Gershkowitz is active in several rare disease and biotech organizations as well as industry, association and nonprofit boards and committees, including: founding chair of BioNJ’s Patient Advocacy Committee; co-founder and board member of Professional Patient Advocates in Life Sciences (PPALS); and former vice-chair of the Board of Directors of the National Organization for Rare Disorders (NORD). She is also part of the Board of Trustees of the Healthcare Institute of NJ (HINJ); BIO’s Government Relations and Rare Disease specialty committees; Together Strong; and the Corporate Alliance of Global Genes. Ms. Gershkowitz was a PharmaVOICE 100 honoree in 2018 and “Heart of BioNJ” Award recipient in 2019.

Podcast   Read the transcript

TRNDS 2019

University of Rochester
Saunders Research Building
Helen Wood Hall Auditorium
255 Crittenden Blvd
Rochester, NY 14642

Date: Friday, September 13
Time: 7:30 am – 4:00pm

TRNDS News

Sign-up for TRNDS updates and rare disease news

  • New Grants will Accelerate Clinical Trials in Rare Neurological Disorders
    READ MORE
  • Neurogene Offers Access to Genetic Testing for Lysosomal Storage Disease
    READ MORE
  • NIH launches 5-year, $10 million study on acute flaccid myelitis
    READ MORE
  • Study refines ALS risk among first-degree relatives of patients with disease
    READ MORE
  • NCATS Director Warns of 'Poorly Understood Public Health Implications of Rare Diseases'
    READ MORE
  • Speeding Up Drug Discovery for Brain Diseases
    READ MORE
  • NIH-Funded Project Aims to Build a ‘Google’ for Biomedical Data
    READ MORE
  • Rare Disease Groups Seek Public Support to Renew Newborn Screening Act in Senate
    READ MORE
  • Jsyne Gershkowitz, Amicus Therapeutics, TRNDS 2019
    (Podcast) Get to know Jayne Gershkowitz, Chief Patient Advocate at Amicus Therapeutics
    READ MORE
  • PJ Brooks, NCATS, NIH, TRNDS
    Meet TRNDS 2019 Speaker PJ Brooks
    READ MORE
  • Rare Pediatric Disease PRVs: FDA Updates Guidance
    READ MORE
  • Batten Disease Study
    Neurogene Opens Natural History Study of CLN7, CLN5 Diseases at UT Southwestern
    READ MORE
  • C-Path and NORD Collaborate to Launch Rare Disease Data Platform
    READ MORE
  • TRNDS 2019 speaker Tauna Batiste, BDSRA
    Meet TRNDS Speaker Tauna Batiste
    READ MORE
  • HD Patients Prefer Less Invasive, No-Placebo Gene Therapy Trials
    READ MORE
  • Evidation & Eli Lilly Study Uses Apple Devices, Apps to Predict Cognitive Impairment
    READ MORE
  • 'Dr. Google' Helps Some Patients Diagnose a Rare Disease
    READ MORE
  • Antisense Drugs for HD, ALS & Prion Could Meet the Need for Brain Treatments
    READ MORE
  • Ultragenyx Partners with GeneTx to Advance Treatment for Angelman Syndrome
    READ MORE
  • Netflix's Medical Investigation Docuseries 'Diagnosis'
    READ MORE
  • NIH All of Us Project Tops 270,000 Sign-ups
    READ MORE
  • FDA Cancer Office Taps Syapse for Real-world Evidence Development
    READ MORE

Latest Tweets

TRNDS Speakers

Room Block

Hilton Garden Inn
Rochester/University
Medical Center

30 Celebration Drive
Rochester, NY 14620

Phone: 585-424-4404

TRNDS Rate: $149/night